

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 10/13/20

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage	
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Infrainguinal revascularized PAD (2) Pediatric VTE (2) COVID-19 MI (PREVENT-HD)	Phase III Phase III Phase III		
	INVOKANA® (canagliflozin) aprocitentan	Treatment of Diabetic Kidney Disease in adults with T2DM (2) Difficult to treat hypertension (2)	Approved 9/19 Phase III	Approved 6/20 Phase III	
Immunology	TREMFYA® (guselkumab)	Psoriatic arthritis Crohn's Disease Pediatric Psoriasis UC Monotherapy	Approved 7/20 Phase IIB/III Phase III Phase IIB/III	Filed 10/19 Phase IIB/III Phase III Phase IIB/III	
	SIMPONI® SIMPONI ARIA®	Pediatric Ulcerative Colitis Polyarticular Juvenile Idiopathic Arthritis (pJIA) Juvenile Psoriatic Arthritis (jPsA)	Phase III Approved 9/20 Approved 9/20	Phase III Phase III	
	STELARA® (ustekinumab)	Pediatric Psoriasis (6-11 year-olds)	Approved 7/20	Approved 1/20	
	Rilpivirine Long Acting nanosuspension for injection pimodivir (JNJ-3872) VAC52150 VAC89220 VAC31518	HIV Infection Influenza A (2) Monovalent Ebola Virus Vaccine HIV Px Vaccine Janssen COVID-19 Vaccine	Complete Response 12/19 <i>Discontinued</i> Phase III Phase III Phase III	Filed 7/19 <i>Discontinued</i> Approved 7/20 Phase III Phase III	
Neuroscience	SPRAVATO® (esketamine)	Major Depressive Disorder with Acute Suicidal Ideation or Behavior	Approved 7/20	Filed 1/20	
	ponesimod paliperidone palmitate 6 month long-acting injectable	Monotherapy for multiple sclerosis Treatment of Schizophrenia	Filed 3/20 Phase III	Filed 3/20 Phase III	
Oncology	DARZALEX®	Relapsed Refractory MM 1+ prior lines w/PomDex (2) Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2) Amyloidosis (AMY 3001) (2) Smoldering multiple myeloma (SMM3001) (2) Frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3019, CEPHEUS) (2) Frontline multiple myeloma transplant eligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3014, PERSEUS) (2)	Phase III Approved 8/20 Filed 9/20 Phase III Phase III Phase III	Phase III Phase III Phase III Phase III	
	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2) Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2) Frontline Chronic Lymphocytic Leukemia in combination with Rituximab (Young and Fit) (ECOG 1912) (2) Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (2) Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (PCYC-1143) (2)	Phase III Phase III Approved 4/20 Phase III Phase III	Phase III Phase III Approved 8/20 Phase III Phase III	
	ERLEADA® (apalutamide)	Localized prostate cancer High risk prostate cancer (PROTEUS)	Phase III Phase III	Phase III Phase III	
	apalutamide/ abiraterone acetate BALVERSA™ (erdafitinib)	Prostate Cancer metastatic castration resistant chemotherapy naïve Urothelial cancer (2) Tumor Agnostic	Phase III Approved 4/19 Phase II	Phase III Phase III Phase II	
	niraparib / abiraterone acetate	Non muscle invasive bladder cancer L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone	Phase II Phase II Phase III	Phase II Phase II Phase III	
	Ciltacabtagene Autoleucel (BCMA CAR-T)	Relapsed refractory multiple myeloma (2) Relapsed refractory multiple myeloma w/1-3 PL (2)	Phase II Phase III	Phase II Phase III	
	Amivantamab (EGFR/cMET)	Non Small Cell Lung Cancer	Phase II	Phase II	
	Pulmonary Hypertension	OPSUMIT®	Fontan-palliated in adolescent (>12 years old) and adult patients Pediatric pulmonary arterial hypertension	Phase III Phase III	Phase III Phase III
		macitentan	Chronic thromboembolic pulmonary hypertension 75mg Pulmonary arterial hypertension 75mg	Phase III Phase III	Phase III Phase III
		UPTRAVI®	Pulmonary arterial hypertension IV Chronic thromboembolic pulmonary hypertension	Filed 9/20 Phase III	Phase III
		Macitentan w/tadalafil FDC	Pediatric pulmonary arterial hypertension Pulmonary arterial hypertension	Phase III Phase III	Phase III Phase III

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir developed in collaboration with ViiV Healthcare Ltd; aprocitentan developed in collaboration with Idorsia; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.



Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of October 13, 2020

NMEs APPROVED	NMEs IN REGISTRATION	NME PLANNED FILINGS 2020-2023*	
Oncology	Neuroscience	Oncology	Neuroscience
ERLEADA® (apalutamide) (EU) Non-metastatic prostate cancer BALVERSA™ (erdafitinib) (US) Urothelial cancer	Ponesimod Monotherapy for multiple sclerosis	Niraparib Metastatic castration-resistant prostate cancer (mCRPC)	Seltorexant Adjunctive treatment for major depressive disorder with insomnia symptoms
Neuroscience		Ciltacabtagene Autoleucl (BCMA CAR-T) Multiple Myeloma	Infectious Diseases & Vaccines
SPRAVATO® (Esketamine) Treatment resistant depression		BALVERSA™ (erdafitinib) (EU) Urothelial cancer	RSV Sr vaccine RSV vaccine
Infectious Diseases & Vaccines		Cusatuzumab Acute myeloid leukemia	Cardiovascular & Metabolism
Monovalent Ebola Vaccine (EU) Ebola virus Disease		Amivantamab (EGFR/cMET) Non Small Cell Lung Cancer	RPGR AAV Gene Therapy X-linked retinitis pigmentosa
		JNJ-7957 (BCMA/CD3), JNJ-7564 (GPC5D/CD3) Multiple myeloma	Aprocitentan Difficult to treat hypertension

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; BCMA CAR-T licensed from Legend Biotech; Cusatuzumab licensed from Argenx; Lazertinib licensed from Yuhan Corporation; JNJ-4500 Anti-NKG2D licensed from Novo Nordisk; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (JNJ-6372, JNJ-7957, JNJ-7564); Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.

